

Stella Capriglione

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/939087/publications.pdf>

Version: 2024-02-01

51
papers

1,226
citations

361413

20
h-index

377865

34
g-index

51
all docs

51
docs citations

51
times ranked

1609
citing authors

#	ARTICLE	IF	CITATIONS
1	First trimester screening for aneuploidy: may combined test and fetal DNA work together?. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 4258-4262.	1.5	4
2	Analysis of ultrasonographic and hystopathologic features of placental invasiveness <i>inÂVitro</i> Fertilization (IVF) pregnancies: a prospective study. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 5631-5638.	1.5	4
3	Postpartum perineal pain: may the vaginal treatment with CO ₂ laser play a key-role in this challenging issue?. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 1190-1197.	1.5	3
4	Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 677-686.	1.5	12
5	Caesarean scar pregnancy: descriptive paper of three different types of management on a series of clinical cases. Przegląd Menopauzalny, 2020, 19, 61-65.	1.3	9
6	Ovarian cancer relapse: From the latest scientific evidence to the best practice. Critical Reviews in Oncology/Hematology, 2019, 140, 28-38.	4.4	31
7	Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients. International Journal of Gynecological Cancer, 2019, 29, 768-771.	2.5	16
8	Assessing HPV vaccination perceptions with online social media in Italy. International Journal of Gynecological Cancer, 2019, 29, 453-458.	2.5	6
9	Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Archives of Gynecology and Obstetrics, 2019, 299, 299-315.	1.7	117
10	Management of gynecological cancer in pregnant patients. Minerva Ginecologica, 2019, 71, 133-145.	0.8	2
11	Effects of Body Mass Index and Biochemical Lipid Levels on Reproductive Outcomes during An Intracytoplasmic Sperm Injection: A Retrospective Study. International Journal of Fertility & Sterility, 2019, 13, 190-195.	0.2	2
12	Implementing the Risk of Endometrial Malignancy Algorithm (REM) adding obesity as a predictive factor: Results of REM-B in a single-center survey. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 225, 51-56.	1.1	6
13	The role of macroplastique implantation in the management of occult urinary stress incontinence. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 225, 124-128.	1.1	2
14	May intraperitoneal irrigation with Betadine improve cesarean delivery outcomes? Results of a 6 yearsâ€™ single centre experience. Journal of Maternal-Fetal and Neonatal Medicine, 2018, 31, 670-676.	1.5	8
15	Anterior colporrhaphy plus inside-out tension-free vaginal tape for associated stress urinary incontinence and cystocele: 10-year follow up results. Neurourology and Urodynamics, 2018, 37, 1144-1151.	1.5	1
16	Placenta accreta and balloon catheterization: the experience of a single center and an update of latest evidence of literature. Archives of Gynecology and Obstetrics, 2018, 298, 83-88.	1.7	25
17	Reply to the letter to the editor. Archives of Gynecology and Obstetrics, 2018, 298, 451-452.	1.7	2
18	The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. International Journal of Gynecological Cancer, 2017, 27, 696-702.	2.5	16

#	ARTICLE	IF	CITATIONS
19	Antiangiogenics and immunotherapies in cervical cancer: an update and futureâ€™s view. <i>Medical Oncology</i> , 2017, 34, 115.	2.5	14
20	Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 9-18.	2.4	21
21	Laser-assisted hatching of human embryos: may two alternative approaches (thinning versus drilling) impact on implant rate?. <i>Lasers in Medical Science</i> , 2017, 32, 1663-1666.	2.1	8
22	Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset. <i>Medical Oncology</i> , 2017, 34, 82.	2.5	11
23	Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. <i>Medical Oncology</i> , 2017, 34, 164.	2.5	51
24	The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 827-839.	2.4	111
25	Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1100.	4.1	29
26	Undescended or absent ovary without uterine anomalies: systematic review and a single center's experience. <i>Minerva Obstetrics and Gynecology</i> , 2017, 69, 35-40.	1.0	2
27	Which are the most common thrombophilic genetic nucleotide polymorphisms in infertile women undergoing an IVF cycle?. <i>Gynecological Endocrinology</i> , 2016, 32, 896-899.	1.7	6
28	Patients treated with neoadjuvant chemotherapy+Âˆradical surgery+Âˆadjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up. <i>Medical Oncology</i> , 2016, 33, 110.	2.5	14
29	Preoperative local staging of endometrial cancer: the challenge of imaging techniques and serum biomarkers. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1291-1298.	1.7	25
30	Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial. <i>Gynecologic Oncology</i> , 2016, 143, 584-588.	1.4	20
31	The challenge of preoperative identification of uterine myomas: Is ultrasound trustworthy? A prospective cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2016, 293, 1235-1241.	1.7	11
32	The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. <i>Tumor Biology</i> , 2016, 37, 4973-4978.	1.8	33
33	Undescended or absent ovary without uterine anomalies: systematic review and a single-center experience. <i>Minerva Ginecologica</i> , 2016, , .	0.8	0
34	Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. <i>Tumor Biology</i> , 2015, 36, 4151-4156.	1.8	37
35	Goal-directed junior ultrasound training in quantitative measurement of crown-rump length and fetal nuchal translucency: evaluation of a specific training program in a specialized center for prenatal diagnosis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 186, 112-113.	1.1	1
36	A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection. <i>Annals of Surgical Oncology</i> , 2015, 22, 4217-4223.	1.5	20

#	ARTICLE	IF	CITATIONS
37	What Is the Rate of Incomplete Fetal Anatomic Surveys During a Secondâ€Trimester Scan?. Journal of Ultrasound in Medicine, 2015, 34, 2187-2191.	1.7	11
38	A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery. Gynecologic Oncology, 2015, 139, 433-438.	1.4	16
39	The impact of gynecologic oncology training in the management of cancer patients: is it really necessary? A prospective cohort study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 184, 19-23.	1.1	7
40	Adjuvant chemotherapy after primary treatments for cervical cancer: a critical point of view and review of the literature. Expert Review of Anticancer Therapy, 2014, 14, 431-439.	2.4	11
41	A critical review on HE4 performance in endometrial cancer: where are we now?. Tumor Biology, 2014, 35, 881-887.	1.8	46
42	Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study. Tumor Biology, 2014, 35, 2741-2746.	1.8	19
43	Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?. Tumor Biology, 2014, 35, 7009-7015.	1.8	42
44	The effects of giving patients verbal or written pre-operative information in gynecologic oncology surgery: a randomized study and the medical-legal point of view. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 177, 67-71.	1.1	41
45	Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?. Gynecologic Oncology, 2013, 128, 579-583.	1.4	60
46	The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumor Biology, 2013, 34, 571-576.	1.8	88
47	Quality of life in patients with endometrial cancer treated with or without systematic lymphadenectomy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 170, 539-543.	1.1	25
48	REM (Risk of Endometrial Malignancy): A Proposal for a New Scoring System to Evaluate Risk of Endometrial Malignancy. Clinical Cancer Research, 2013, 19, 5733-5739.	7.0	28
49	Does Extensive Upper Abdomen Surgery During Primary Cytoreduction Impact on Long-term Quality of Life?. International Journal of Gynecological Cancer, 2013, 23, 442-447.	2.5	15
50	Does HE4 have a role as biomarker in the recurrence of ovarian cancer?. Tumor Biology, 2012, 33, 2117-2123.	1.8	54
51	Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. Gynecologic Oncology, 2012, 127, 290-296.	1.4	83